NCT02987543 2023-10-06Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)AstraZenecaPhase 3 Completed387 enrolled 16 charts 2 FDA
NCT01942837 2022-10-24Study of Enzalutamide in Patients With Castration-resistant Prostate CancerDana-Farber Cancer InstitutePhase 2 Completed67 enrolled 17 charts